Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 6, 2007, Pages 515-521

  Stone, Anne ^a   Saiman, Lisa ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Epidemiology; Eradication; Methicillin resistant; Small colony variant; Staphylococcus aureus; Virulence

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFALEXIN; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; LINEZOLID; MACROLIDE; MONOBACTAM DERIVATIVE; MONOCLONAL ANTIBODY; PENICILLIN DERIVATIVE; PLACEBO; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; VANCOMYCIN;

AEROSOL; ANTIBIOTIC PROPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM COLONY; CLINICAL LABORATORY; CLINICAL TRIAL; CULTURE MEDIUM; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG SENSITIVITY; ERADICATION THERAPY; HUMAN; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; PATHOGENESIS; PERSISTENT INFECTION; PHENOTYPE; PREVALENCE; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; METHICILLIN; METHICILLIN RESISTANCE; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE; WORLD HEALTH;

EID: 34848890028     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282efbbac     Document Type: Review

References (67)

1. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004; 17:57-71.
2. Cystic Fibrosis Foundation. Patient Registry 2005 Annual Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2006.
3. Ren CL, Morgan WJ, Konstan MW, et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007; 42:513-518. This paper describes the clinical significance of MRSA colonization/infection compared with MSSA among patients with cystic fibrosis using a large multicenter database.
4. Elizur A, Orschein RC, Ferkol TW, et al. Panton-valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infections in patients with cystic fibrosis. Chest 2007; 131:1718-1725. This single center study describes PVL-positive MRSA among patients with cystic fibrosis and its clinical significance.
5. Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001; 84:160-162.
6. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505-520.
7. Haas JP, Evans AM, Preston KE, et al. Risk factors for surgical site infection after cardiac surgery: the role of endogenous flora. Heart Lung 2005; 34:108-114.
8. Graham PL 3rd, Morel A, Zhou J, et al. Epidemiology of methicillin-susceptible Staphylococcus aureus in the neonatal intensive care unit. Infect Control Hosp Epidemiol 2002; 23:677-682.
9. Lowy FD, Miller M. New methods to investigate infectious disease transmission and pathogenesis - Staphylococcus aureus disease in drug users. Lancet Infect Dis 2002; 2:605-612.
10. Charlebois ED, Bangsberg DR, Moss NJ, et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002; 34:425-433.
11. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006; 193:172-179.
12. Goerke C, Kraning K, Stern M, et al. Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients. J Infect Dis 2000; 181:984-989.
13. Saiman L, O'Keefe M, Graham PL 3rd, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37:1313-1319.
14. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593-598.
15. Hussain FM, Boyle-Vavra S, Daum RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000; 19:1163-1166.
16. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999; 29:797-800.
17. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24 (5 Suppl):S6-S52.
18. Sharp SE, Searcy C. Comparison of mannitol salt agar and blood agar plates for identification and susceptibility testing of Staphylococcus aureus in specimens from cystic fibrosis patients. J Clin Microbiol 2006; 44:4545-4546. This article demonstrates the efficacy of using mannitol salt agar to identify S. aureus from cystic fibrosis respiratory tract specimens.
19. Zhou J, Garber E, Desai M, et al. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol 2006; 44:1547-1549. This is an examination of adherence to clinical laboratory guidelines in the USA, which demonstrates improved adherence to recommendations over time.
20. Shreve MR, Butler S, Kaplowitz HJ, et al. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol 1999; 37:753-757.
21. Vergison A, Denis O, Deplano A, et al. National survey of molecular epidemiology of Staphylococcus aureus colonization in Belgian cystic fibrosis patients. J Antimicrob Chemother 2007; 59:893-899. This study demonstrates how the inconsistent use of selective media alters S. aureus prevalence rates.
22. Besier S, Smaczny C, von Mallinckrodt C, et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 2007; 45:168-172. This paper investigates the clinical significance of SCV S. aureus and describes the association with persistent infection and advanced disease.
23. Kahl B, Herrmann M, Everding AS, et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998; 177:1023-1029.
24. Hoffman LR, Deziel E, D'Argenio DA, et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2006; 103:19890-19895. The authors describe how co-infection with P. aeruginosa selects for aminoglycoside-resistant and SCV S. aureus. This serves as an excellent demonstration of the difficulties surrounding the identification of S. aureus in the clinical laboratory.
25. Kipp F, Kahl BC, Becher K, et al. Evaluation of two chromogenic agar media for recovery and identification of Staphylococcus aureus small-colony variants. J Clin Microbiol 2005; 43:1956-1959.
26. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005; 3:948-958.
27. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003; 111:1265-1273.
28. Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for healthcare-associated infection: 2001-2003. Pediatr Infect Dis J 2006; 25:343-348.
29. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003; 24:451-455.
30. Prunier AL, Malbruny B, Laurans M, et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 2003; 187:1709-1716.
31. Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-1254.
32. Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence? Pediatr Pulmonol 2005; 40:471-476.
33. Ratjen F, Comes G, Paul K, et al. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001; 31:13-16.
34. Stutman HR, Lieberman JM, Nussbaum E, et al. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002; 140:299-305.
35. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; 3:CD001912.
36. UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic treatment for cystic fibrosis: report of the UK Cystic Fibrosis Trust Antibiotic Group, 2nd ed. Bromley, Kent, UK: UK Cystic Fibrosis Trust Antibiotic Group; 2002.
37. McCaffery K, Olver RE, Franklin M, Mukhopadhyay S. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax 1999; 54:380-383.
38. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15:194-222.
39. Shapera RM, Warwick WJ, Matsen JM. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis. J Pediatr 1981; 99:647-650.
40. Wright FL, Harper J. Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis. Lancet 1970; 1:9-14.
41. Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2006; 12:440-444.
42. Ramsey BW, Wentz KR, Smith AL, et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991; 144:331-337.
43. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28:321-328.
44. Aaron SD, Kottachchi D, Ferris WJ, et al. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J 2004; 24:631-637.
45. Jung A, Kleinau I, Schonian G, et al. Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. Eur Respir J 2002; 20:1457-1463.
46. Garske LA, Kidd TJ, Gan R, et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 2004; 56:208-214.
47. Maiz L, Canton R, Mir N, et al. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 1998; 26:287-289.
48. Solis A, Brown D, Hughes J, et al. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003; 36:189-195.
49. Macfarlane M, Leavy A, McCaughan J, et al. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 2007; 65:231-236.
50. Beringer PM, Appleman MD. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med 2000; 6:545-550.
51. Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol 2002; 33:221-223.
52. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21:263-274.
53. Saralaya D, Peckham DG, Hulme B, et al. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J Antimicrob Chemother 2004; 53:25-28.
54. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48:281-284.
55. Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006; 27:300-302. This case report describes linezolid-resistant S. aureus in a patient with cystic fibrosis.
56. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004; 10:515-523.
57. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. Jama 2003; 290:1749-1756.
58. Prunier AL, Malbruny B, Tande D, et al. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother 2002; 46:3054-3056.
59. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006; 61:895-902. This randomized trial demonstrates the efficacy of chronic azithromycin in patients not infected with P. aeruginosa.
60. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167:841-849.
61. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23-30.
62. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190-1196.
63. Ramsey BW, Dorkin JL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328:1740-1746.
64. Lee JC, Par J, Shepherd SE, et al. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65:4146-4151.
65. Vernachio J, Bayer AS, Le T, et al. Anticlumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 2003; 47:3400-3406.
66. Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004; 22 (Suppl):S39-S43.
67. Fattom AI, Horwith G, Fuller S, et al. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004; 22:880-887.